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CANCER 
Cancer (medical term: malignant neoplasm) is a class of diseases in which a 
group of cells display uncontrolled growth (division beyond the normal limits), 
invasion (intrusion on and destruction of adjacent tissues), and sometimes metastasis 
(spread to other locations in the body via lymph or blood). The branch of medicine 
concerned with the study, diagnosis, treatment, and prevention of cancer is oncology. 
Cancer may affect people at all ages, even fetuses, but the risk for most 
varieties increases with age.[1] Cancer causes about 13% of all human deaths.[2] Nearly 
all cancers are caused by abnormalities in the genetic material of the transformed 
cells.[3] These abnormalities may be due to the effects of carcinogens, such as tobacco 
smoke, radiation, chemicals, or infectious agents. Other cancer-promoting genetic 
abnormalities may be randomly acquired through errors in DNA replication, or are 
inherited, and thus present in all cells from birth. The heritability of cancers are 
usually affected by complex interactions between carcinogens and the host's genome. 
New aspects of the genetics of cancer pathogenesis, such as DNA methylation and 
microRNAs are increasingly recognized as important. 
Genetic abnormalities found in cancer typically affect two general classes of 
genes. Cancer-promoting oncogenes are typically activated in cancer cells, giving 
those cells new properties, such as hyperactive growth and division, protection against 
programmed cell death, loss of respect for normal tissue boundaries, and the ability to 
become established in diverse tissue environments. Tumor suppressor genes are then 
inactivated in cancer cells, resulting in the loss of normal functions in those cells, such 
as accurate DNA replication, control over the cell cycle, orientation and adhesion 
within tissues, and interaction with protective cells of the immune system. 
    The following closely related terms may be used to designate abnormal 
growths: 
 Tumor or tumour: originally, it meant any abnormal swelling, lump or mass 
 Neoplasm: the scientific term to describe an abnormal proliferation of 
genetically altered cells. Neoplasms can be benign or malignant:  
o Malignant neoplasm or malignant tumor: synonymous with cancer.  
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o Benign neoplasm or benign tumor: a tumor (solid neoplasm) that stops 
growing by itself, does not invade other tissues and does not form 
metastases.  
 Invasive tumor is another synonym of cancer. The name refers to invasion of 
surrounding tissues. 
 Pre-malignancy, pre-cancer or non-invasive tumor: A neoplasm that is not 
invasive but has the potential to progress to cancer (become invasive) if left 
untreated. These lesions are, in order of increasing potential for cancer, atypia, 
dysplasia and carcinoma in situ.  
CLASSIFICATION: 
Carcinoma: Malignant tumors derived from epithelial cells This group represents 
the most common cancers, including the most common forms of breast, prostate, lung 
and colon cancer. 
 
Sarcoma : Malignant tumors derived from connective tissue or mesenchymal 
cells 
Lymphoma and leukaemia: Malignancies derived from hematopoietic cells. 
Germ cell tumor : Tumors derived from totipotent cells.  
Blastic tumor or Blastoma: A tumor (Usually malignant) which resembles an 
immature or embryonic tissue. 
SIGNS AND SYMPTOMS 
Symptoms of cancer metastasis depend on the location of the tumor. 
Roughly, cancer symptoms can be divided into three groups: 
Local symptoms: unusual lumps or swelling (tumor), hemorrhage (bleeding), pain 
and/or ulceration. Compression of surrounding tissues may cause symptoms such as 
jaundice (yellowing the eyes and skin).  
Symptoms of metastasis (spreading): enlarged lymph nodes, cough and hemoptysis, 
hepatomegaly (enlarged liver), bone pain, fracture of affected bones and neurological 
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symptoms. Although advanced cancer may cause pain, it is often not the first 
symptom.  
Systemic symptoms: weight loss, poor appetite, fatigue and cachexia, (wasting), 
excessive sweating (night sweats), anemia and specific paraneoplastic phenomena, i.e. 
specific conditions that are due to an active cancer, such as thrombosis or hormonal 
changes.  
 
PATHOPHYSIOLOGY: 
Cancer is a diverse class of diseases which differ widely in their causes and 
biology. Any organism, even plants, can acquire cancer. Nearly all known cancers 
arise gradually, as errors build up in the cancer cell and its progeny. Anything which 
replicates (our cells) will probabilistically suffer from errors (mutations). Cancer is 
thus a progressive disease, and these progressive errors slowly accumulate until a cell 
begins to act contrary to its function in the animal. 
Mutation:Chemical carcinogens 
Cancer pathogenesis is traceable back to DNA mutations that impact cell 
growth and metastasis. Substances that cause DNA mutations are known as mutagens, 
and mutagens that cause cancers are known as carcinogens. Particular substances have 
been linked to specific types of cancer. Tobacco smoking is associated with many 
forms of cancer,[4] and causes 90% of lung cancer.[5] Prolonged exposure to asbestos 
fibers is associated with mesothelioma[6].  
Mutation: ionizing radiation 
Sources of ionizing radiation, such as radon gas, can cause cancer. Prolonged 
exposure to ultraviolet radiation from the sun can lead to melanoma and other skin 
malignancies.[7] 
Viral or bacterial infection 
Some cancers can be caused by infection with pathogens.[8] Many cancers 
originate from a viral infection; this is especially true in animals such as birds, but 
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also in humans, as viruses are responsible for 15% of human cancers worldwide. The 
main viruses associated with human cancers are human papillomavirus, hepatitis B 
and hepatitis C virus, Epstein-Barr virus, and human T-lymphotropic virus. 
Hormonal imbalances 
Some hormones can act in a similar manner to non-mutagenic carcinogens in 
that they may stimulate excessive cell growth. A well-established example is the role 
of hyperestrogenic states in promoting endometrial cancer. 
Immune system dysfunction 
HIV is associated with a number of malignancies, including Kaposi's sarcoma, 
non-Hodgkin's lymphoma, and HPV-associated malignancies such as anal cancer and 
cervical cancer.  
Heredity 
Most forms of cancer are sporadic, meaning that there is no inherited cause of the 
cancer. There are, however, a number of recognised syndromes where there is an 
inherited predisposition to cancer, often due to a defect in a gene that protects against 
tumor formation. Famous examples are: 
 certain inherited mutations in the genes BRCA1 and BRCA2 are associated 
with an elevated risk of breast cancer and ovarian cancer  
 tumors of various endocrine organs in Multiple Endocrine Neoplasia (MEN 
types 1, 2a, 2b)  
 Li-Fraumeni syndrome (various tumors such as osteosarcoma, breast cancer, 
soft tissue sarcoma, brain tumors) due to mutations of p53  
 Turcot syndrome (brain tumors and colonic polyposis)  
 Familial adenomatous polyposis an inherited mutation of the APC gene that 
leads to early onset of colon carcinoma.  
 Hereditary Nonpolyposis Colorectal Cancer (HNPCC, also known as Lynch 
syndrome) can include familial cases of colon cancer, uterine cancer, gastric 
cancer, and ovarian cancer, without a preponderance of colon polyps.  
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 Retinoblastoma, when occurring in young children, is due to a hereditary 
mutation in the retinoblastoma gene.  
 Down syndrome patients, who have an extra chromosome 21, are known to  
develop malignancies such as leukemia and testicular cancer, though the 
reasons for this difference are not well understood.  
Biological properties of cancer cells 
In a 2000 article by Hanahan and Weinberg, the biological properties of malignant 
tumor cells were summarized as follows:[9] 
 Acquisition of self-sufficiency in growth signals, leading to unchecked 
growth.  
 Loss of sensitivity to anti-growth signals, also leading to unchecked growth.  
 Loss of capacity for apoptosis, in order to allow growth despite genetic errors 
and external anti-growth signals.  
 Loss of capacity for senescence, leading to limitless replicative potential 
(immortality)  
 Acquisition of sustained angiogenesis, allowing the tumor to grow beyond the 
limitations of passive nutrient diffusion.  
 Acquisition of ability to invade neighbouring tissues, the defining property of 
invasive carcinoma.  
CELL BIOLOGY & CANCER: 
Cancer is a group of more than 100 diseases that develop across time and 
involve the uncontrolled division of the body's cells. Although cancer can develop in 
virtually any of the body's tissues, and each type of cancer has its unique features, the 
basic processes that produce cancer are quite similar in all forms of the disease. 
 All of the cells produced by division of this first, ancestral cell and its 
progeny also display inappropriate proliferation. A tumor, or mass of cells, formed of 
these abnormal cells may remain within the tissue in which it originated, or it may 
begin to invade nearby tissues. An invasive tumor is said to be malignant, and cells 
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shed into the blood or lymph from a malignant tumor are likely to establish new 
tumors (metastases) throughout the body. 
 
 
Figure No.1 - The stages of tumor development. A malignant tumor develops across 
time, as shown in this diagram. This tumor develops as a result of four mutations, but 
the number of mutations involved in other types of tumors can vary. We do not know 
the exact number of mutations required for a normal cell to become a fully malignant 
cell, but the number is probably less than ten. a. The tumor begins to develop when a 
cell experiences a mutation that makes the cell more likely to divide than it normally 
would. b. The altered cell and its descendants grow and divide too often, a condition 
called hyperplasia. At some point, one of these cells experiences another mutation that 
further increases its tendency to divide. c. This cell's descendants divide excessively 
and look abnormal, a condition called dysphasia. As time passes, one of the cells 
experiences yet another mutation. d. This cell and its descendants are very abnormal 
in both growth and appearance. If the tumor that has formed from these cells is still 
contained within its tissue of origin, it is called in situ cancer. In situ cancer may 
remain contained indefinitely. e. If some cells experience additional mutations that 
allow the tumor to invade neighboring tissues and shed cells into the blood or lymph, 
the tumor is said to be malignant. The escaped cells may establish new tumors 
(metastases) at other locations in the body.  
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Figure No.2 - Two schemes by which tumors can develop. Most—if not all—human 
cancer appears to be monoclonal 
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CANCER: CELL CYCLE 
The cell cycle, or cell-division cycle, is the series of events that take place in a 
cell leading to its division and duplication (replication). 
The cell cycle consists of five distinct phases: G1 phase, S phase (synthesis), 
G2 phase (collectively known as interphase) and M phase (mitosis). M phase is itself 
composed of two tightly coupled processes: mitosis, in which the cell's chromosomes 
are divided between the two daughter cells, and cytokinesis, in which the cell's 
cytoplasm divides forming distinct cells. Activation of each phase is dependent on the 
proper progression and completion of the previous one. Cells that have temporarily or 
reversibly stopped dividing are said to have entered a state of quiescence called G0 
phase. 
 
 
Figure No.3- Schematic of the cell cycle. outer ring: I = Interphase, M = Mitosis; 
inner ring: M = Mitosis, G1 = Gap 1, G2 = Gap 2, S = Synthesis; not in ring: G0 = Gap 
0/Resting. The duration of mitosis in relation to the other phases has been exaggerated 
in this diagram. 
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Table No.1 
State Phase Abbreviation Description 
quiescent/ 
senescent Gap 0 G0 
A resting phase where the cell has left the cycle 
and has stopped dividing. 
Interphase 
Gap 1 G1 
Cells increase in size in Gap 1. The G1
checkpoint control mechanism ensures that 
everything is ready for DNA synthesis. 
Synthesis S DNA replication occurs during this phase. 
Gap 2 G2 
During the gap between DNA synthesis and 
mitosis, the cell will continue to grow. The G2
checkpoint control mechanism ensures that 
everything is ready to enter the M (mitosis) 
phase and divide. 
Cell 
division Mitosis M 
Cell growth stops at this stage and cellular 
energy is focused on the orderly division into 
two daughter cells. A checkpoint in the middle 
of mitosis (Metaphase Checkpoint) ensures that 
the cell is ready to complete cell division. 
Resting (G0 phase) 
The term "post-mitotic" is sometimes used to refer to both quiescent and 
senescent cells. Nonproliferative cells in multicellular eukaryotes generally enter the 
quiescent G0 state from G1 and may remain quiescent for long periods of time, 
possibly indefinitely (as is often the case for neurons).  
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 G1 phase 
The first phase within interphase, from the end of the previous M phase until 
the beginning of DNA synthesis is called G1 (G indicating gap). During this phase the 
biosynthetic activities of the cell, which had been considerably slowed down during 
M phase, resume at a high rate. This phase is marked by synthesis of various enzymes 
that are required in S phase, mainly those needed for DNA replication. Duration of G1 
is highly variable, even among different cells of the same species. 
 S phase 
The ensuing S phase starts when DNA synthesis commences; when it is 
complete, all of the chromosomes have been replicated, i.e., each chromosome has 
two (sister) chromatids. Thus, during this phase, the amount of DNA in the cell has 
effectively doubled, though the ploidy of the cell remains the same. Rates of RNA 
transcription and protein synthesis are very low during this phase. An exception to 
this is histone production, most of which occurs during the S phase.[10,11,12] 
 G2 phase 
The cell then enters the G2 phase, which lasts until the cell enters mitosis. 
Again, significant protein synthesis occurs during this phase, mainly involving the 
production of microtubules, which are required during the process of mitosis. 
Inhibition of protein synthesis during G2 phase prevents the cell from undergoing 
mitosis. 
Mitosis (M Phase) 
The relatively brief M phase consists of nuclear division (karyokinesis) and 
cytoplasmic division (cytokinesis). In plants and algae, cytokinesis is accompanied by 
the formation of a new cell wall. The M phase has been broken down into several 
distinct phases, sequentially known as prophase, Prometaphase, metaphase, anaphase 
and telophase leading to cytokinesis. 
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Regulation of eukaryotic cell cycle 
 
Figure No.4 -Regulation of the cell cycle involves processes crucial to the survival of 
a cell, including the detection and repair of genetic damage as well as the prevention 
of uncontrolled cell division. The molecular events that control the cell cycle are 
ordered and directional; that is, each process occurs in a sequential fashion and it is 
impossible to "reverse" the cycle. 
 Role of cyclins and CDKs 
Two key classes of regulatory molecules, cyclins and cyclin-dependent 
kinases (CDKs), determine a cell's progress through the cell cycle.[13] Many of the 
genes encoding cyclins and CDKs are conserved among all eukaryotes components. 
Cyclins form the regulatory subunits and CDKs the catalytic subunits of an activated 
heterodimer.  
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Inhibitors: 
 
 
 
Figure No.5 -Overview of signal transduction pathways involved in apoptosis, also 
known as "programmed cell death". 
Role in tumor formation: 
A disregulation of the cell cycle components may lead to tumor formation. As 
mentioned above, some genes like the cell cycle inhibitors, RB, p53 etc., when they 
mutate, may cause the cell to multiply uncontrollably, forming a tumor. Although the 
duration of cell cycle in tumor cells is equal to or longer than that of normal cell 
cycle, the proportion of cells that are in active cell division (versus quiescent cells in 
G0 phase) in tumors is much higher than that in normal tissue. Thus there is a net 
increase in cell number as the number of cells that die by apoptosis or senescence 
remains the same 
MECHANISM:  
Cancer is fundamentally a disease of regulation of tissue growth. In order for a 
normal cell to transform into a cancer cell, genes which regulate cell growth and 
differentiation must be altered.[14] Genetic changes can occur at many levels, from 
gain or loss of entire chromosomes to a mutation affecting a single DNA nucleotide. 
There are two broad categories of genes which are affected by these changes.  
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Oncogenes may be normal genes which are expressed at inappropriately high 
levels, or altered genes which have novel properties. In either case, expression of 
these genes promotes the malignant phenotype of cancer cells. Tumor suppressor 
genes are genes which inhibit cell division, survival, or other properties of cancer 
cells. Tumor suppressor genes are often disabled by cancer-promoting genetic 
changes. Typically, changes in many genes are required to transform a normal cell 
into a cancer cell.[15] 
Epigenetics 
Epigenetics is the study of the regulation of gene expression through chemical, 
non-mutational changes in DNA structure. The theory of epigenetics in cancer 
pathogenesis is that non-mutational changes to DNA can lead to alterations in gene 
expression. Normally, oncogenes are silent, for example, because of DNA 
methylation. Loss of that methylation can induce the aberrant expression of 
oncogenes, leading to cancer pathogenesis. 
Oncogenes 
Oncogenes promote cell growth through a variety of ways. Many can produce 
hormones, a "chemical messenger" between cells which encourage mitosis, the effect 
of which depends on the signal transduction of the receiving tissue or cells.  
The change of an oncogene from normal to cancerous function can be caused 
by a simple point mutation in the sequence of a gene. For example, a change in the ras 
oncogene, located on human chromosome 11, from guanine to cytosine is frequently 
associated with bladder cancer. This simple change results in glycine at amino acid 
#12 being substituted with a valine. This dramatically changes the function of the G-
protein encoded by the ras gene. Normally, the protein cycles from an inactive to 
active state by change the bound GDP to GTP. The mutation does not allow the 
release of GTP, and the protein is continuously active. Because the signal delivered 
by the ras oncoprotein is continuously delivered, the cell continues to grow and 
divide. This unabated growth leads to the bladder cancer.   
The following table summarizes the types of molecular changes that can be 
associated with the activation of an oncogene.  
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Table No.2 
 
TUMOR MARKERS: 
Tumor markers are molecules occurring in blood or tissue that are associated 
with cancer and whose measurement or identification is useful in patient diagnosis or 
clinical management. The ideal marker would be a "blood test" for cancer in which a 
positive result would occur only in patients with malignancy, one that would correlate 
with stage and response to treatment and that was easily and reproducibly measured.  
Tumor markers can be used for one of four purposes:  
1) Screening a healthy population or a high risk population for the presence of 
cancer; 
2) Making a diagnosis of cancer or of a specific type of cancer; 
3) Determining the prognosis in a patient; 
4) Monitoring the course in a patient in remission or while receiving surgery, 
radiation, or chemotherapy. 
Molecular 
Change Effect On Oncogene 
Translocation 
Philadelphia chromosome contains a bcr1/abl fusion that activates the abl
protein kinase activity; Burkitt lymphoma result from the placement of the 
c-myc next to an enhancer in B lymphocytes 
Point Mutations See ras discussion above 
Deletions See v-erbB discussion above 
Insertional 
activation 
A retrovirus without an oncogene may insert near a proto-oncogene and 
activate the proto-oncogene by increasing its expression 30-100 fold. This 
activation is not immediate, but can take several months. The LTRs of 
retroviruses contain powerful promoters and enhancer sequences that 
presumably are responsible for the increased expression. The insertion can 
occur on either side of the proto-oncogene or in its intron. This type of 
activation has been associated with c-myc and c-myb. 
Amplification Amplification of the proto-oncogene has also been associated with the onset of cancer. This has been best studied in cell culture. 
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Tumor Antigens 
Include markers defined by both monoclonal antibodies and polyclonal 
antisera, often the so called oncofetal antigens. The oncofetal substances, present in 
embryo or fetus, diminish to low levels in the adult but reappear in the tumor.  
 
Carcinoembryonic Antigen 
Tumor marker, CEA: Carcinoembryonic antigen (CEA) is a protein found in 
many types of cells but associated with tumors and the developing fetus. CEA is 
tested in blood. The normal range is <2.5 ng/ml in an adult non-smoker and <5.0 
ng/ml in a smoker.  
Alpha-Fetoprotein 
Alpha-Fetoprotein is a normal fetal serum protein synthesized by the liver, 
yolk sac, and gastrointestinal tract that shares sequence homology with albumin. It is 
a major component of fetal plasma, reaching a peak concentration of 3 mg/ml at 12 
weeks of gestation.  
CA 125 
CA125 is an antigen present on 80 percent of nonmucinous ovarian 
carcinomas. It is defined by a monoclonal antibody (OC125) that was generated by 
immunizing laboratory mice with a cell line established from human ovarian 
carcinoma.  
Prostate-Specific Antigen 
The PSA screening test is a blood test that looks for a specific tumor marker. 
In general, tumor markers are produced by the tumor itself or by our body in response 
to the presence of cancer or non-cancerous conditions. 
Bladder tumor antigen (BTA)  
BTA is found in the urine of many patients with bladder cancer. It may be a 
sign of some non-cancerous conditions, too, such as kidney stones or urinary tract 
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infections. The results of the test are reported as either positive (BTA is present) or 
negative (BTA is not present).  
CA 27.29  
CA 27.29 is another marker that can be used to follow patients with breast 
cancer during or after treatment. This test measures the same marker as the CA 15-3 
test. 
Calcitonin  
Calcitonin is a hormone produced by cells called Para follicular C cells in the 
thyroid gland. It normally helps regulate blood calcium levels. Normal calcitonin 
levels are below 5 to 12 pg/ml (pictograms per milliliter). (A pictogram is one 
trillionth of a gram.) In medullary thyroid carcinoma (MTC), a rare cancer that starts 
in the Para follicular C cells, blood levels of this hormone are often greater than 100 
pg/ml.   
HER2 (also known as HER2/neu, erbB-2, or EGFR2)  
HER2 is a protein that tells breast cancer cells to grow. It is elevated in some 
breast cancers. Higher than normal levels can be found in some other cancers, too. 
The HER2 level is usually found by testing a sample of the cancer tissue itself, not the 
blood. About 1 in 5 breast cancers test positive for HER2.   
Human chronic gonadotropin (HCG)  
HCG (also known as beta-HCG) blood levels are elevated in patients with 
some types of testicular and ovarian cancers (germ cell tumors) and in gestational 
trophoblastic disease, mainly choriocarcinoma. They are also higher in some people 
with mediastinal germ cell tumors cancers in the middle of the chest (the 
mediastinum) that start in the same cells as germ cell tumors of the testicles and 
ovaries.   
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Immunoglobulin  
Immunoglobulins are not really tumor markers but antibodies, which are blood 
proteins normally made by immune system cells to help fight germs. There are many 
types of immunoglobulin, including IgA, IgG, IgD, and IgM. 
PREVENTION 
Modifiable ("lifestyle") risk factors: 
The vast majority of cancer risk factors are environmental or lifestyle-related 
in nature leading to the claim that cancer is a largely preventable disease.[16] Examples 
of modifiable cancer risk factors include alcohol consumption (associated with 
increased risk of oral, esophageal, breast, and other cancers), smoking (although 20% 
of women with lung cancer have never smoked, versus 10% of men[17]), physical 
inactivity (associated with increased risk of colon, breast, and possibly other cancers), 
and being overweight / obese (associated with colon, breast, endometrial, and possibly 
other cancers). . 
Diet: 
The consensus on diet and cancer is that obesity increases the risk of Proposed 
dietary interventions for primary cancer risk reduction generally gain support from 
epidemiological association studies. Examples of such studies include reports that 
reduced meat consumption is associated with decreased risk of colon cancer,[18] and 
reports that consumption of coffee is associated with a reduced risk of liver cancer.[19] 
Vitamins 
Epidemiological studies have shown that low vitamin D status is correlated to 
increased cancer risk.  
Chemoprevention 
The concept that medications could be used to prevent cancer is an attractive 
one. Daily use of tamoxifen, a selective estrogen receptor modulator (SERM), 
typically for 5 years, has been demonstrated to reduce the risk of developing breast 
			 																																																																									Introduction 
                                            
18	
 
cancer in high-risk women by about 50%. A recent study reported that the selective 
estrogen receptor modulator raloxifene has similar benefits to tamoxifen in preventing 
breast cancer in high-risk women, with a more favorable side effect profile.[20] 
Raloxifene is a SERM like tamoxifen; it has been shown (in the STAR trial) to 
reduce the risk of breast cancer in high-risk women equally as well as tamoxifen. In 
this trial, which studied almost 20,000 women, raloxifene had fewer side effects than 
tamoxifen, though it did permit more DCIS to form.  
Finasteride, a 5-alpha-reductase inhibitor, has been shown to lower the risk of 
prostate cancer, though it seems to mostly prevent low-grade tumors.[21] The effect of 
COX-2 inhibitors such as rofecoxib and celecoxib upon the risk of colon polyps have 
been studied in familial adenomatous polyposis patients[22] and in the general 
population.[23, 24]  
Genetic testing 
Genetic testing for high-risk individuals is already available for certain cancer-
related genetic mutations. Carriers of genetic mutations that increase risk for cancer 
incidence can undergo enhanced surveillance, chemoprevention, or risk-reducing 
surgery. Early identification of inherited genetic risk for cancer, along with cancer-
preventing interventions such as surgery or enhanced surveillance, can be lifesaving 
for high-risk individuals. 
Table No.3 
Gene Cancer types Availability 
BRCA1, BRCA2 Breast, ovarian, pancreatic Commercially available for clinical specimens 
MLH1, MSH2, MSH6, 
PMS1, PMS2 
Colon, uterine, small bowel, 
stomach, urinary tract 
Commercially available for 
clinical specimens 
			 																																																																									Introduction 
                                            
19	
 
Vaccination 
Prophylactic vaccines have been developed to prevent infection by oncogenic 
infectious agents such as viruses, and therapeutic vaccines are in development to 
stimulate an immune response against cancer-specific epitopes.[25] A preventive 
human papillomavirus vaccine exists that targets certain sexually transmitted strains 
of human papillomavirus that are associated with the development of cervical cancer 
and genital warts. The only two HPV vaccines on the market as of October 2007 are 
Gardasil and Cervarix. There is also a hepatitis B vaccine, which prevents infection 
with the hepatitis B virus, an infectious agent that can cause liver cancer. A canine 
melanoma vaccine has also been developed.[26 ] 
TREATMENT:  
Cancer can be treated by surgery, chemotherapy, radiation therapy, 
immunotherapy, monoclonal antibody therapy or other methods. The choice of 
therapy depends upon the location and grade of the tumor and the stage of the disease, 
as well as the general state of the patient (performance status).  
Surgery 
 Non-hematological cancers can be cured if entirely removed by surgery but 
this is not always possible. When the cancer has metastasized to other sites in the 
body prior to surgery, complete surgical excision is usually impossible. In the 
Halstedian model of cancer progression, tumors grow locally, then spread to the 
lymph nodes, then to the rest of the body. This has given rise to the popularity of 
local-only treatments such as surgery for small cancers. Even small localized tumors 
are increasingly recognized as possessing metastatic potential. 
Examples of surgical procedures for cancer include mastectomy for breast 
cancer and prostatectomy for prostate cancer. 
 
			 																																																																									Introduction 
                                            
20	
 
Radiation therapy 
Radiation therapy (also called radiotherapy, X-ray therapy, or irradiation) is 
the use of ionizing radiation to kill cancer cells and shrink tumors. Radiation therapy 
can be administered externally via external beam radiotherapy (EBRT) or internally 
via brachytherapy. The effects of radiation therapy are localised and confined to the 
region being treated. Radiation therapy injures or destroys cells in the area being 
treated (the "target tissue") by damaging their genetic material, making it impossible 
for these cells to continue to grow and divide. Radiation therapy may be used to treat 
almost every type of solid tumor, including cancers of the brain, breast, cervix, larynx, 
lung, pancreas, prostate, skin, stomach, uterus, or soft tissue sarcomas. Radiation is 
also used to treat leukemia and lymphoma. 
Chemotherapy 
The term "chemotherapy" usually refers to cytotoxic drugs which affect 
rapidly dividing cells in general, in contrast with targeted therapy . Chemotherapy 
drugs interfere with cell division in various possible ways, e.g. with the duplication of 
DNA or the separation of newly formed chromosomes. Most forms of chemotherapy 
target all rapidly dividing cells and The treatment of some leukaemias and lymphomas 
requires the use of high-dose chemotherapy, and total body irradiation (TBI) 
Targeted therapies 
Targeted therapy, which first became available in the late 1990s, has had a 
significant impact in the treatment of some types of cancer, and is currently a very 
active research area. This constitutes the use of agents specific for the deregulated 
proteins of cancer cells. Small molecule targeted therapy drugs are generally 
inhibitors of enzymatic domains on mutated, overexpressed, or otherwise critical 
proteins within the cancer cell. Prominent examples are the tyrosine kinase inhibitors 
imatinib (Gleevec/Glivec) and gefitinib (Iressa). 
Monoclonal antibody therapy is another strategy in which the therapeutic 
agent is an antibody which specifically binds to a protein on the surface of the cancer 
cells. Examples include the anti-HER2/neu antibody trastuzumab (Herceptin) used in 
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breast cancer, and the anti-CD20 antibody rituximab, used in a variety of B-cell 
malignancies. 
Immunotherapy : 
Cancer immunotherapy refers to a diverse set of therapeutic strategies 
designed to induce the patient's own immune system to fight the tumor. Contemporary 
methods for generating an immune response against tumours include intravesical 
BCG immunotherapy for superficial bladder cancer, and use of interferons and other 
cytokines to induce an immune response in renal cell carcinoma and melanoma 
patients. Vaccines to generate specific immune responses are the subject of intensive 
research for a number of tumours, notably malignant melanoma and renal cell 
carcinoma. Sipuleucel-T is a vaccine-like strategy in late clinical trials for prostate 
cancer in which dendritic cells from the patient are loaded with prostatic acid 
phosphatase peptides to induce a specific immune response against prostate-derived 
cells. 
Hormonal therapy 
The growth of some cancers can be inhibited by providing or blocking certain 
hormones. Common examples of hormone-sensitive tumors include certain types of 
breast and prostate cancers. Removing or blocking estrogen or testosterone is often an 
important additional treatment. In certain cancers, administration of hormone 
agonists, such as progestogens may be therapeutically beneficial. 
Angiogenesis inhibitors 
Angiogenesis inhibitors prevent the extensive growth of blood vessels 
(angiogenesis) that tumors require to survive. Some, such as bevacizumab, have been 
approved and are in clinical use.  
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CANCER STATISTICS [27] 
Each year, the American Cancer Society estimates the number of new cancer 
cases and deaths expected in the United States in the current year and compiles the 
most recent data on cancer incidence, mortality, and survival based on incidence data 
from the National Cancer Institute, Centers for Disease Control and Prevention, and 
the North American Association of Central Cancer Registries and mortality data from 
the National Center for Health Statistics. Incidence and death rates are standardized by 
age to the 2000 United States standard million population. A total of 1,479,350 new 
cancer cases and 562,340 deaths from cancer are projected to occur in the United 
States in 2009. Overall cancer incidence rates decreased in the most recent time period 
in both men (1.8% per year from 2001 to 2005) and women (0.6% per year from 1998 
to 2005), largely because of decreases in the three major cancer sites in men (lung, 
prostate, and colon and rectum [colorectum]) and in two major cancer sites in women 
(breast and colorectum). Overall cancer death rates decreased in men by 19.2% 
between 1990 and 2005, with decreases in lung (37%), prostate (24%), and colorectal 
(17%) cancer rates accounting for nearly 80% of the total decrease. Among women, 
overall cancer death rates between 1991 and 2005 decreased by 11.4%, with decreases 
in breast (37%) and colorectal (24%) cancer rates accounting for 60% of the total 
decrease. The reduction in the overall cancer death rates has resulted in the avoidance 
of about 650,000 deaths from cancer over the 15-year period. This report also 
examines cancer incidence, mortality, and survival. 
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Table No-4 
          CONTAINING CANCER DEATH BY SITE AND SEX[28] 
Sr.No Male Death occurs Female Death occurs 
1 Lung 95,400 Lung 62,000 
2 Prostate 40,400 Breast 46,000 
3 Colon & rectum 27,200 Colon & rectum 28,100 
4 Pancreas 13,200 Pancreas 13,800 
5 Lymphoma 12,820 Lymphoma 11,330 
6 Leukaemia 11,100 Leukaemia 9,300 
7 Stomach 8,800 Stomach 5,900 
8 Eosaphagus 8,200 Ovary 14,500 
9 Liver 7,700 Liver 14,500 
10 Bladder 7,500 Brain 6,000 
11 Brain 7,300 Uterus 10,700 
12 Kidney 7,100 Kidney 5,000 
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CANCER: HERBAL MEDICINE 
 
Extensive research during the last 30 years has revealed much about the biology of
cancer. Drugs used to treat most cancers are those that can block cell signaling, including
growth factor signaling (eg:,epidermal growth factor); prostaglandin
production(eg:,COX-2); inflammation(eg:,inflammatory cytokines:NF-kappaB,TNF,IL-1,
IL-6, chemokines); drug resistance gene products(eg:multi-drug resistance); cell cycle
proteins(  eg:Cyclin D1 and cyclin E); angiogenesis(eg: vascular endothelial growth
factor); invasion (eg: matrix metalloproteinases); antiapoptosis (eg:bcl-2, bcl-X(L),
XIAP, surviving, FLIP); and cellular proliferation (eg:c-myc, AP-1, growth factors).
Numerous reports have suggested that ayurvedic plants and their components mediate
their effects by modulating several of these recently identified therapeutic targets.
However, ayurvedic medicine requires rediscovery in light of our current knowledge of
allopathic(modern) medicine. In particular, cancer patients are reported to benefit from
treatment with herbal medicine and survivability in many cases is significantly enhanced.
Recent studies showed the anti-oxidative and superoxide scavenging activities of
individual active components of herbal medicine for their inhibitory activities on lipid
peroxidation and anti-cancer properties. Individual herbal medicines show antipyretic,
analgesic and anti-inflammatory and anti-cancer effects. Numerous in vitro studies of
herbal medicine on different cell lines and in vivo study of herbal medicine have been
reported. However, the mechanism of actions remain unclear.  
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        REVIEW OF LITERATURE 
 
Kalita S, et al., (2014) has studied the Chlorambucil and ascorbic acid-mediated 
anticancer activity and hematological toxicity in Dalton's ascites lymphoma-bearing 
mice. Based on these study combination treatment of mice with ascorbic acid plus 
chlorambucil showed less histopathological changes in kidney as compared to 
chlorambucil treatment alone, thus, ascorbic acid is effective in reducing 
chlorambucil-induced renal toxicity in the hosts.[29] 
Martha KR, et al., (2013) has studied the Cisplatin and dietary ascorbic acid     
mediated changes in the mitochondria of dalton’s lymphoma bearing 
mice.Combination treatment increase the antitumor activity and decrease the cisplatin 
induced toxicity in the host.[30] 
 
Surya bali Prasad, et al., (2010) has studied the Cyclophosphamide and ascorbic 
acid-mediated ultrastructural and biochemical changes in Dalton's lymphoma cells in 
vivo. The observed ascorbic acid plus cyclophosphamide-mediated decrease in 
reduced glutathione (GSH) in tumor cells may play an important role in the antitumor 
activity of cyclophosphamide by weakening cellular antioxidant-mediated defense 
mechanism, thereby increasing tumor cell's susceptibility to cell death. [31] 
 
Nicol BM et al., (2002) has studied the Sialic acid changes in Dalton's lymphoma-
bearing mice after cyclophosphamide and cisplatin treatment. The study showed that 
significant decrease in the sialic acid content of Dalton's lymphoma cells after 
cisplatin or cyclophosphamide treatment may bring about specific changes in tumour 
cells which could be associated with tumour regression. [32] 
 
Osama A.Badari, et al., (1999) studied the Thymoquinone attenuates ifosfamide-
induced Fanconi syndrome in rats and enhances its antitumor activity in mice.These 
observations demonstrate that TQ may improve the therapeutic efficacy of IFO by 
decreasing IFO-induced nephrotoxicity and improving its antitumor activity. [33] 
 
Kirsten Börner, et al., (2000) studied the Metabolism of Ifosfamide to 
Chloroacetaldehyde Contributes to Antitumor Activity In Vivo. On a molar basis 
                                                                       Review of Literature 
  
26	
 
chloroacetaldehyde was seven times less potent as 4-hydroxyifosfamide.These study 
showed that the basis of achieved AUC values, chloroacetaldehyde seems to exhibit a 
similar antitumor activity to 4-hydroxyifosfamide. [34] 
 
C Bokemeyer, et al., (1996) has studied the Silibinin protects against cisplatin-
induced nephrotoxicity without compromising cisplatin or ifosfamide anti-tumour 
activity. he current data form the basis for a clinical study using cisplatin-based 
combination chemotherapy including silibinin, in patients with testicular cancer in 
order to reduce the acute and long- term nephrotoxic potential of cisplatin. [35] 
 
M Markman, et al., (1992) has studied the Ifosfamide and mesna in previously 
treated advanced epithelial ovarian cancer: activity in platinum-resistant 
disease.These study showed that Single-agent ifosfamide has modest but unequivocal 
activity in platinum-resistant ovarian cancer. Further studies of this drug used as a 
front-line agent along with an organoplatinum compound or as part of a dose-
intensification program with bone marrow, peripheral stem cell, or colony-stimulating 
factor support are indicated. In addition, single-agent ifosfamide is a reasonable 
standard second-line treatment strategy in appropriately selected patients with 
platinum-refractory ovarian cancer. [36] 
 
Kuśnierczyk H, et al., (1986) has studied the Antitumor Activity of Optical Isomers 
of Cyclophosphamide, Ifosfamide and Trofosfamide as Compared to Clinically Used 
Racemate+. These study shown that the stereodifferentiation of anti-tumor effect of 
enantiomers was not outstanding although quite consistently in favor of levorotatory 
forms. [37] 
 
W. Brade,et al., (1986) has studied the Comparative activity of ifosfamide and 
cyclophosphamide.More comparative controlled clinical trials are needed in ovarian 
cancer, breast cancer, malignant lymphomas, sarcomas and cervical cancer, in which 
IFO has already shown sufficient single-agent activity.These study showed that to its 
lower level of cross-resistance with a variety of heterocyclic products, but also with 
other alkylating agents, in addition to its use in induction chemotherapy, IFO is an 
important second-line agent in many clinical situations. [38] 
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Muthu Irulappan Sriram, et al., (2010) has studied the Antitumor activity of silver 
nanoparticles in Dalton’s lymphoma ascites tumor model. These findings confirm the 
antitumor properties of AgNPs, and suggest that they may be a cost-effective 
alternative in the treatment of cancer and angiogenesis-related disorders. [39] 
 
Meghna R Adhvaryu, et al., (2008) has studied the Anti-tumor activity of four 
Ayurvedic herbs in Dalton lymphoma ascites bearing mice and their short-term in 
vitro cytotoxicity on DLA-cell-line.The study showed All the four herbs showed in 
vitro cytotoxic activity against DLA cell-line. Moreover inter group comparison of all 
the four herbs for anti-tumor activity showed efficacy in the following order--T. 
cordifolia > Z. mauritiana > or = C. longa > O. sanctum respectively. [40] 
 
Benjamin RS, et al.,(1993) has studied the Single-agent ifosfamide studies in 
sarcomas of soft tissue and bone: the M.D. Anderson experience.These study showed 
that Ifosfamide has demonstrated clinically useful antitumor activity in our hands 
against most sarcoma subtypes. Our studies suggest a dose-response relationship for 
ifosfamide. At a total dose of 6 g/m2 per course, the overall response rate was 10%; at 
10 g/m2 per course, it rose to 21%. Future clinical trials will determine ifosfamide's 
role in combination chemotherapy and more clearly define the best schedule or 
schedules for the uroprotective administration of mesna. [41] 
 
H. Glazman-kuśnierczyk, et al., (1992) has studied the Antitumor Activity 
Evaluation of Bromine-Substituted Analogues of Ifosfamide. I. Stereodifferentiaton of 
Biological Effects Amd Selection of the Most Potent Compounds.These study showed 
that the effect four compounds which have been shown therapeutically more effective 
than both referential drugs, were selected for further evaluation in mice bearing 
advanced tumours. [42] 
 
Vanhoefer U, et al.,(2000) has studied the Ifosfamide-based drug combinations, 
preclinical evaluation of drug interactions and translation into the clinic.These study 
showed that the data reported here demonstrate that in vitro ifosfamide may potentiate 
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the antitumor activity of a variety of cytotoxic agents and therefore merits further 
clinical evaluation in drug combinations (eg, taxanes, anthracyclines). [43] 
 
B Samuel Thavamani, et al.,(2014) has studied the Anticancer activity of 
cissampelos pareira against dalton's lymphoma ascites bearing mice.These study 
showed that C. pariera exhibited significant in vitro and in vivo anti-tumor activities 
and that it was reasonably imputable to its increasing endogenous mechanism of 
antioxidant property. [44] 
 
Shivakumar. B.S, et al., has studied the Evaluation of In -Vitro Anticancer Activity 
of Barlaria buxifolia Linn Extracts Against Dalton's Lymphoma Ascites Cell line .The 
study showed that the present study suggested that the methanolic extract of root from 
Barlaria buxifolia is cytotoxic to DLA cell lines. The presence of flavonoids and 
related phytoconstituents may be responsible for the activity. Further studies 
warranted, for isolation of the constituents responsible for the activity and also to 
explore the exact mechanism of action of the activity. [45] 
 
Purushoth Prabhu, et al., has studied that the Invitro and Invivo anticancer activity 
of Ethanolic extract of Canthium Parviflorum Lam on DLA and Hela cell lines. These 
study showed that Anticancer activity of Canthium Parviflorum was may be due to 
flavonoid present in the plant. Further studies are also in process to evaluate the most 
potent fraction of the plant and to isolate the constituents of the fractions. [46] 
 
Christian M. Kurbacher, et al., (1996) has studied that Ascorbic acid (vitamin C) 
improves the antineoplastic activity of doxorubicin, cisplatin, and paclitaxel in human 
breast carcinoma cells in vitro. Combination effects between Vit C and DDP or Tx 
were partly synergistic and partly additive or sub additive whereas a consistent 
synergism was found between Vit C and DOX. [47] 
 
Perrone G, et al.,(2009)Ascorbic acid inhibits antitumor activity of bortezomib in 
vivo. Therefore, our results for the first time show that vitamin C can significantly 
reduce the activity of bortezomib treatment in vivo; and importantly, suggest that 
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patients receiving treatment with bortezomib should avoid taking vitamin C dietary 
supplements. [48] 
 
Yukitoshi Takemuraa, et al.,(2010) has studied the High dose of ascorbic acid 
induces cell death in mesothelioma cells. This study shows that ascorbic acid may 
have benefits for patients with mesothelioma. [49] 
 
Anirudha giri, et al.,(1998) has studied the Vitamin C mediated protection on 
cisplatin induced mutagenicity in mice. These study shows  combined treated hosts 
the frequency of all the mutagenic parameters were always significantly less than that 
treated with cisplatin alone. These findings suggest a protective role of ascorbic acid 
against cisplatin induced mutagenic potentials. [50] 
 
Steve Harakeh, et al.,(2006) has studied the Ascorbic Acid Induces Apoptosis in 
Adult T-cell Leukemia. These study shows that Ascorbic acid was found to reduce the 
proliferation of cells and induce apoptosis by the modulation of p53, p21, Bcl-2 and 
Bax. [51] 
 
Ewan Cameron, et al., (1979) has studied the Ascorbic acid and cancer review. This 
study showed that there is evidence from both human and experimental animal studies 
that the development and progress of cancer evokes an increased requirement for 
ascorbic acid. [52] 
 
Aristides Polyzos, et al., (2009) has studied the Cisplatin–Ifosfamide–Gemcitabine 
as Salvage Chemotherapy in Ovarian Cancer Patients Pretreated with Platinum 
Compounds and Paclitaxel. These study shows that the efficacy of this three-drug 
combination in patients with platinum-resistant tumors was moderate. [53] 
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FOCUS OF THE PRESENT STUDY 
 
The Ifosfamide induced major side effects include myelosuppression, 
pancytopenia, anaemia, thrombocytopaenia and/or leukopaenia, renal toxicity, 
gastrointestinal toxicity, fertility disorders and neurotoxcity. Hepatotoxicity and 
pneumotoxicity have been reported only infrequently. In the endeavor to decrease 
drug induced toxicity in the host without decreasing the therapeutic efficacy, the use 
of anticancer drugs such as cisplatin, cyclophosphamide, paclitaxel and arsenic 
trioxide in combination with vitamin C (2-Oxo-L-threo-hexono-1,4-lactone-2,3-
enediol. 
 
The significance of vitamin C in relation to cancer chemotherapy and 
possibility of development of Ifosfamide induced toxicity in mice, the present study 
has been undertaken to assess the modulatory effect of dietary ascorbic acid on 
Ifosfamide mediated antitumor efficacy and haematological and renal toxicity in 
mice.    
 
 
PLAN OF WORK 
 
Anticancer activity of Ifosfamide and ascorbic acid mediated haemotological 
toxicity in Dalton’s ascites Lymphoma bearing mice. 
 
It is planned to carryout this work as outlined below. 
1. In-vivo evaluation of anticancer activity. 
a. Induction of cancer using DLA cell lines 
b. Treatment protocol. 
c. Study of various biochemical parameters in the blood and Derived 
parameters. 
d. Histopathological parameters. 
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BIOCHEMICAL PARAMETERS 
 
 Hematological Parameters 
 WBC Count 
 RBC Count 
 Platelet Count 
 Hemoglobin content 
 Packed cell Volume 
 
 Serum Enzyme and Lipid Profile 
 Aspartate amino Transferase (AST) 
 Alanine amino Transferase   (ALT) 
 Alkaline Phosphatase            (ALP) 
 Total Cholesterol                   (TC)    
 Triglyceride                           (TG) 
               
DERIVED PARAMETERS 
 
 Body weight 
 Percentage increase in Life span 
 Cancer cell count 
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IFOSFAMIDE 
Ifosfamide (also marketed as Ifex) is a nitrogen mustard alkylating agent used 
in the treatment of cancer.[54] It is sometimes abbreviated as "IFO".[55] 
 
SYNONYM 
3-(2-Chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-
oxazaphosphorine 2-oxide 
 
USES 
It is given as a treatment for a variety of cancers, including: 
 Testicular cancer 
 Breast cancer 
 Lymphoma (Hodgkin and nonHodgkin) 
 Soft tis sue sarcoma 
 Osteos arcoma or bone tumor 
 Lung cancer 
 Cervical cancer 
 Ovarian cancer 
 
ADMINISTRATION 
It is a white powder which, when prepared for use in chemotherapy, becomes 
a clear, colorless fluid. The delivery is intravenous. Ifosfamide is often used in 
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conjunction with mesna to avoid internal bleeding in the patient, in particular 
hemorrhagic cystitis. Ifosfamide is given quickly, and in some cases can be given as 
quickly as an hour. 
 
DRUG MECHANISM 
The exact mechanism of ifosfamide has not been determined, but appears to 
be similar to other alkylating agents. Ifosfamide requires biotransformation in the 
liver by mixed-function oxidases (cytochrome P450 system) before it becomes active. 
After metabolic activation, active metabolites of ifosfamide alkylate or bind with 
many intracellular molecular structures, including nucleic acids. The cytotoxic action 
is primarily through the alkylation of DNA, done by attaching the N-7 position of 
guanine to its reactive electrophilic groups. The formation of inter and intra strand 
cross-links in the DNA results in cell death. 
 
VOLUME OF DISTRIBUTION 
Ifosfamide volume of distribution (Vd) approximates the total body water 
volume, suggesting that distribution takes place with minimal tissue binding. 
Following intravenous administration of 1.5 g/m2 over 0.5 hour once daily for 5 days 
to 15 patients with neoplastic disease, the median Vd of ifosfamide was 0.64 L/kg on 
Day 1 and 0.72 L/kg on Day 5. When given to pediatric patients, the volume of 
distribution was 21±1.6 L/m^2. 
 
PROTEIN BINDING 
Ifosfamide shows little plasma protein binding. 
 
METABOLISM 
Primarily hepatic. Ifosfamide is metabolized through two metabolic pathways: 
ring oxidation ("activation") to form the active metabolite, 4-hydroxy-ifosfamide and 
side-chain oxidation to form the inactive metabolites, 3-dechloro-ethylifosfamide or 
2-dechloroethylifosfamide with liberation of the toxic metabolite, chloroacetaldehyde. 
Small quantities (nmol/mL) of ifosfamide mustard and 4-hydroxyifosfamide are 
detectable in human plasma. Metabolism of ifosfamide is required for the generation 
                                                     Drug Profile  
   
 
34	
 
of the biologically active species and while metabolism is extensive, it is also quite 
variable among patients. 
 
ROUTE OF ELIMINATION 
Ifosfamide is extensively metabolized in humans and the metabolic pathways 
appear to be saturated at high doses. After administration of doses of 5 g/m2 of 14C-
labeled Ifosfamide, from 70% to 86% of the dosed radioactivity was recovered in the 
urine, with about 61% of the dose excreted as parent compound. At doses of 1.6–2.4 
g/m2 only 12% to 18% of the dose was excreted in the urine as unchanged drug 
within 72 hours. 
 
HALF LIFE 
7-15 hours. The elimination half-life increase appeared to be related to the 
increase in Ifosfamide volume of distribution with age. 
 
TOXICITY 
LD50 (mouse) = 390-1005 mg/kg, LD50 (rat) = 150-190 mg/kg. Side effects 
include nausea, vomiting and myelosuppression. Toxic effects include central nervous 
system toxicity (confusion, hallucinations) and urotoxic effects (cystitis, blood in 
urine). 
 
SIDE EFFECTS 
More common 
 Agitation 
 black, tarry stools 
 blood in the urine 
 chest pain 
 confusion 
 cough or hoarseness 
 fever or chills 
                                                     Drug Profile  
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 frequent urination 
 hallucinations (seeing, hearing, or feeling things that are not there) 
 lower back or side pain 
 painful or difficult urination 
 pale skin 
 shortness of breath 
 sore throat 
 sores, ulcers, or white spots on the lips or in the mouth 
 swollen glands 
 troubled breathing with exertion 
 unusual bleeding or bruising 
 unusual tiredness or weakness 
Less common 
 Abdominal or stomach pain or tenderness 
 bleeding gums 
 bluish color 
 changes in skin color 
 clay colored stools 
 dark urine 
 decreased appetite 
 dizziness 
 headache 
 itching 
 loss of appetite 
                                                     Drug Profile  
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 nausea and vomiting 
 pain 
 pinpoint red spots on the skin 
 skin rash 
 swelling of the feet or lower legs 
 yellow eyes or skin 
Rare 
 Blurred vision 
 burning, numbness, tingling, or painful sensations 
 confusion 
 convulsions (seizures) 
 dizziness, faintness, or lightheadedness when getting up suddenly from a 
lying or sitting position 
 fast or irregular heartbeat 
 sweating 
 troubled breathing 
 unsteadiness or awkwardness 
 weakness in the arms, hands, legs or feet 
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EXPERIMENTAL MODEL [56] 
For the study of anticancer activity, an experimental model is selected in such 
way that it would satisfy the following condition; 
 The animal should develop cancer rapidly and reproducibly.  
 Pathological changes in the site of induction should result from cancer 
formation. 
 The symptoms should be ameliorated or prevented by a drug treatment 
effective in human beings.  
 The drug tested should be administered orally.  
 Drug dosage should approximate the optimum therapeutic range for 
human, scaled the test animal weight.   
 
Selection Grouping and Acclimatization of Laboratory Animal [57] 
Male Swiss albino mice (20-25 gm) were produced from animal experimental 
laboratory, and used throughout the study. They were housed in micro nylon boxes in 
a control environment (temp 25±2°C) and 12 hrs dark /light cycle with standard 
laboratory diet and water ad libitum. The study was conducted after obtaining 
institutional animal ethical committee clearance. As per the standard practice, the 
mice were segregated based on their gender and quarantined for 15 days before the 
commencement of the experiment. They were fed on healthy diet and maintained in 
hygienic environment in our animal house. 
 
Technique for Inducing Tumor  
Various technique for induction of cancer in animals, viz, chemically induced 
(using DMBA/croton oil, etc) [58] virus induced, cell line induced (sarcoma – 180, 
ULCA fibro sarcoma and Jensen sarcoma, mouse lung fibroblast cells L-929, 
Dalton’s Lymphoma Ascites (DLA), Ehrlich Ascites Carcinoma (EAC) [59,60,61] 
methods have been used in experimental studies of anticancer activity. 
 
 In the present study, cell lines induced cancer in mice was used to evaluate the 
anticancer activity.  
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EVALUATION OF ANTICANCER ACTIVITY 
 
Induction of cancer using DLA cells 
 
Dalton’s Lymphoma Ascites (DLA) cells were supplied by Amala Cancer 
Research Center, Trissur, Kerala, India. The cells maintained in vivo in Swiss albino 
mice by intraperitoneally transplantation. While transforming the tumor cells to the 
grouped animal the DLA cells were aspirated from peritoneal cavity of the mice using 
saline. The cell counts were done and further dilution were made so that total cell 
should be 1 x 106 , this dilution was given intraperitoneally. Let the tumor grow in the 
mice for minimum seven days before starting treatments.  
 
Treatment Protocol    
Swiss Albino mice were divided in to five group of six each. All the animals 
in four groups were injected with DLA cells (1 x 106 cells per mouse) 
intraperitoneally, and the remaining one group is normal control group. 
 
 Group 1 served as the normal control.  
 Group 2 served as the tumor control. Group 1 and 2 receives normal diet and Water.  
 Group 3 served as the Treatment control, was treated with injection Ifosfamide at 10  
    mg/kg body weight, Intraperitoneally. [62]  
 Group 4 served as the treatment control, which was treated with Ascorbic acid at 10 
mg/kg body weight, through Intraperitoneally. 
 
          Group 5 served as treatment control, which was treated with Ifosfamide + Ascorbic 
acid at 10 mg/kg body weight each, through Intraperitoneally. 
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METHODOLOGY 
 
Sample collection 
 
          In this study, drug treatment was given after the 24 hrs of inoculation, once 
daily for 14 days.  
 
 On day 14, after the last dose, all mice from each group were sacrificed; the 
blood was withdrawn from each mice by retro orbital plexus method and the 
following parameters were checked. 
 
1. Hematological parameters 
a. WBC count   
b. RBC count  
c. Hb content 
d. Platelet count 
e. Packed cell volume 
2.   Serum enzyme and lipid profile 
a. Total Cholesterol                      (TC) 
b. Triglycerides                             (TG) 
c. Aspartate amino Transferase   (AST) 
d. Alanine amino Transferase       (ALT) 
e. Alkaline Phosphatase               (ALP) 
     3.    Derived parameter 
f. Body weight 
g. Life span (%) 
                 h.   Cancer Cell Count 
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EVALUATION OF CLINICAL PARAMETERS [63-66] 
 
1) Cancer cell count[67] 
 
The fluid (0.1ml) from the peritoneal cavity of each mouse was withdrawn by 
sterile syringe and diluted with 0.8 ml of ice cold Normal saline or sterile Phosphate 
Buffer Solution and 0.1 ml of tryphan blue (0.1 mg/ml) and total numbers of the 
living cells were counted using heamocytometer. 
 
                               No of cells Dilution 
   Cell count = ------------------------------------------              
                        Area × Thickness of liquid film 
 
2) Hematological parameters 
 
i) WBC count 
ii) RBC count 
iii) Platelet count 
iv) Hemoglobin 
v)  Packed Cell Volume 
 
i) WBC count 
 The total WBC count was found to be increased in cancer control, when 
compared with normal and treated tumor-bearing mice. The total WBC count were 
found to decrease significantly in animals treated with plant extract when compared 
with cancer control, indicating that the antitumor nature of the extract.[68] 
 
ii) RBC and Hb 
 RBC and Hb content decreases with tumor bearing mice when compared with 
Normal control mice. 
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iii) Platelets 
 In Hodgkin lymphoma, increased in platelet count often reported in laboratory 
finding. Hence, I investigated this parameter in the study. [69] 
 
iv) Packed cell volume  
           In any case of anemia the packed cell volume is decreases.  
 
SERUM ENZYME AND LIPID PROFILE 
                 The serum was analysed for the following parameters 
(a) Aspartate amino Transferase   (AST) 
(b) Alanine amino Transferase      (ALT) 
(c) Alkaline Phosphatase              (ALP) 
(d) Total Cholesterol                     (TC) 
(e) Triglyceride                              (TG) 
 
1. TOTAL CHOLESTEROL AND TRIGLYCERIDE (lipid profile) 
 Abnormal blood lipid profile has been associated with cancer. In Hodgkin 
lymphoma, high cholesterol level and low triglyceride level has been reported. Hence 
I investigated this parameter in the study. [70] 
 
2. LIVER ENZYMES (AST, ALT, ALP). 
 Abnormal liver function seen in patient with Hodgkin lymphoma, [49] that 
these liver enzyme levels markedly increase in tumor bearing mice. ALP is an enzyme 
mainly derived from the liver, bones and in lesser amount from intestines, placenta, 
kidneys and leukocytes. An increase in ALP levels in the serum is frequently 
associated with the variety of disease. [71] ALP comprises a group of enzyme that 
catalyzes the phosphate esters in an alkaline environment, generating an organic 
radical and inorganic phosphate. 
 Markedly elevated serum ALP, hyperalakline-phosphatasemia, is seen 
predominantly with more specific disorders; including malignant biliary cirrhosis, 
hepatic lymphoma and sarcoidosis. [72] Hence, I investigated this parameter in this 
study. 
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DERIVED PARAMETERS [56] 
  
1. Body weight: 
   All the mice were weighed, from the beginning to 15th day of the study. 
Average increase in body weight on the 15th day was determined. 
 
2. Percentage increase in life span (ILS) [68] 
 
 % ILS was calculated by the following formulae 
   %ILS = 100x1groupcontrolofspanLife
grouptreatedofspanLife      
 All biochemical investigations were done by using COBAS MIRA PLUS-S 
Auto analyzer from Roche Switzerland. 
 Hematological test are carried out in COBAS MICROS OT 18 from Roche. 
 Newly added Hi-Tech instruments MAX MAT used for an auto analyzer 
for all biochemistry investigations in blood sample. 
 
Effect of Ifosfamide and ascorbic acid on Survival Time 
 Animals in the first batch were divided into five groups of six animals each. 
Except the normal control group, the remaining groups were inoculated with DLA 
cells (1x106 cells/mouse) intraperitoneally on day ‘0’ and treatment with Ifosfamide 
and ascorbic acid started 24 hrs after inoculation, at a dose of 10 mg/kg/day each 
through I.P. The normal and tumor control group was treated with same volume of 
0.9% sodium chloride solution. All the treatments were given for fourteen days. The 
increase in life span (ILS) of each group, consisting of 6 mice was noted. 
 The antitumor efficacy of Ifosfamide and ascorbic acid was compared with 
combination of that of Ifosfamide and ascorbic acid 10 mg/kg/day each, i.p, for 14 
days). The ILS of the treated groups was compared with that of the control group 
using the following calculation: 
                   Increase in lifespan = [(T - C) / C] x 100 
Where    T = number of days the treated animal survived. 
  C = number of days control animals survived. 
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Table	No.	5	
EFFECT OF IFOSFAMIDE AND ASCORBIC ACID ON HEMATOLOGICAL PARAMETERS 
 
 
 
 
 
 
 
 
 
G1 – Normal Control,     G2 – Cancer Control,   G3 – Treatment control (ifosfamide),  
G4 – Treatment control (ascorbic acid),  G5 – Treatment control (ifosfamide + ascorbic acid) 
All values are expressed as mean ± SEM for 6 animals in each group. 
**a – Values are significantly different from control (G1) at P < 0.01 
**b – Values are significantly different from cancer control (G2) at P < 0.01 
. 
 
TREATMENT Total WBC Cells /mlx103 
Rbc Count 
Mill/cumm 
Hb 
Gm/dl PCV % 
Platelets 
Lakhs/cumm
G1 11.80 ±3.60 5.30±0.86 12.65 ±1.30 15.46±2.45 5.80±0.90 
G2 13.50 ±3.60a** 4.80±0.20a** 9.54  ±0.92a** 26.40±3.25a** 4.75±0.62a**
G3 14.20 ±2.75b** 3.90±0.78b** 10.60±1.45b** 30.40±1.50b** 4.50±0.96b**
G4 12.42 ±2.90b** 5.15±0.58b** 12.50±1.32b** 16.40±1.70b** 5.10 ±0.80b**
G5 13.20±2.75b** 4.73±0.50b** 11.53±1.06b** 22.26±1.85b** 5.30±0.92b**
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EFFECT OF IFOSFAMIDE AND ASCORBIC ACID ON HEMATOLOGICAL 
PARAMETERS 
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EFFECT OF IFOSFAMIDE AND ASCORBIC ACID ON HEMATOLOGICAL 
PARAMETERS 
 
 
 
Figure No. 7 
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EFFECT OF IFOSFAMIDE AND ASCORBIC ACID ON HEMATOLOGICAL 
PARAMETERS 
 
 
 
Figure No. 8 
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EFFECT OF IFOSFAMIDE AND ASCORBIC ACID ON HEMATOLOGICAL 
PARAMETERS 
 
 
 
Figure No. 9 
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EFFECT OF IFOSFAMIDE AND ASCORBIC ACID ON HEMATOLOGICAL 
PARAMETERS 
 
 
 
Figure No. 10 
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Table No.6 
EFFECT OF IFOSFAMIDE	AND	ASCORBIC	ACID ON THE LIFE SPAN, BODY WEIGHT AND CANCER CELL COUNT OF 
TUMOR INDUCED MICE 
Treatment Number of 
animals 
% ILS Life span Increase in Body 
weight grams 
Cancer cell count 
ml X 106 
G1 6 >>31 days 2.70±0.62 - 
G2 6 48% 6.80±0.96a** 4.70±0.40a** 
G3 6 78% 4.85±0.70b** 2.59±0.22b** 
G4 6 84% 3.55±0.88b** 2.10±0.30b** 
G5 6 80% 5.10±0.86b** 2.30±0.25b** 
 
G1 – Normal Control,     G2 – Cancer Control,   G3 – Treatment control (Ifosfamide),  
G4 – Treatment control (ascorbic acid),  G5 – Treatment control (Ifosfamide+ascorbic acid) 
All values are expressed as mean ± SEM for 6 animals in each group. 
**a – Values are significantly different from control (G1) at P < 0.01 
**b – Values are significantly different from cancer control (G2) at P < 0.01 
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EFFECT OF	IFOSFAMIDE	AND	ASCORBIC	ACID ON THE LIFE SPAN, 
BODY WEIGHT AND CANCER CELL COUNT OF TUMOR INDUCED 
MICE 
 
 
 
Figure No. 11 
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EFFECT OF	IFOSFAMIDE	AND	ASCORBIC	ACID ON THE LIFE SPAN, 
BODY WEIGHT AND CANCER CELL COUNT OF TUMOR INDUCED 
MICE 
 
 
 
Figure No. 12 
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EFFECT OF	IFOSFAMIDE	AND	ASCORBIC	ACID ON THE LIFE SPAN, 
BODY WEIGHT AND CANCER CELL COUNT OF TUMOR INDUCED 
MICE 
 
 
 
Figure No. 13 
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DISCUSSION 
 
In the studies related with the assessment of antitumor activity of various 
drugs, ascites Dalton’s lymphoma has been commonly used as an important murine 
experimental tumor model [73,74,75,76]. As this malignant Dalton’s Lymphoma is related 
with the lymphocytes (mainly T-lymphocytes), it may also be helpful in correlating 
some human cancer related with lymphocytes such as precursor T-cell 
leukemia/lymphoma, non-Hodgkin lymphoma, Burkitt’s lymphoma, BCL , Follicular 
lymphoma, MALT lymphoma etc. Ifosfamide and its derivates are alkylating agents 
which have been used against various malignancies particularly chronic lymphocytic 
leukemia (CLL)[77,78]. Ifosfamide has also been used in combination with other agents 
such as fluderabine [79], 2-(morpholin-4-yl)-benzo[h]chomen-4-one [80], levamisole [81] 
against various cancers. The host survival data from the present studies indicate 
significant increase in survivability of the tumor bearing mice treated with Ascorbic 
acid (AA) plus Ifosfamide, as compared to the group of mice treated with either agent 
alone, suggesting additive/ synergistic antitumor activity of AA and Ifosfamide 
against murine Dalton’s lymphoma.  
 
Several mechanisms have been elucidated to explain the AA-mediated 
enhancement in the antitumor activity and apoptosis of anticancer drugs. There is also 
increasing evidence that AA is selectively cytotoxic to some types of tumor cells, 
functioning as a pro-oxidant, rather than anti-oxidant. It has been reported that AA 
induces apoptosis with the generation of GSH oxidation and H2O2 accumulation in 
acute myeloid leukemia (AML) cells. Induction of apoptosis in AA-treated AML cells 
involved a dose-dependent increase of Bax protein, release of cytochrome C from 
mitochondria to cytosol, activation of caspase 9 and caspase 3, and cleavage of poly 
(ADP-ribose) polymerase [82]. The pro-oxidant activity of ascorbic acid is due to its 
ability to redox-cycle with transition metal ions, and thereby stimulates the formation 
of species such as superoxide, hydrogen peroxide and hydroxyl radicals.  
 
Development of Ifosfamide induced blood related toxicity such as 
myelosuppression- pancytopenia, anaemia, thrombocytopaenia and/or 
leukopaenia[77,83,84] is another problem. Depletion in erythrocytes leads to iron 
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deficiency, anemia [85] and is a frequent complication of cancer diseases. Tung et 
al.[86] mentioned that the reduction in the values of blood parameters like RBC, WBC 
and Hb may be attributed to the hyperactivity of bone marrow, which leads to 
production of red blood cells with impaired integrity that are easily destroyed in the 
circulation. In the present study also a significant decrease in the haematological 
parameters i.e. RBC, WBC counts and Hb contents, were observed in tumor-bearing 
animals after Ifosfamide treatment (Table 5). AA plus Ifosfamide co-treatment of 
tumor-bearing animals caused significant recovery in these haematological values 
(Table 5). Combination treatment with AA plus Ifosfamide resulted in a significant 
(P_0.05) decrease and betterment in abnormal RBCs as compared to Ifosfamide 
alone.  
 
The decreased life span of RBCs and anemia may be correlated with decreased 
blood antioxidant capacity [87]. In addition to oxygen transport, RBCs also function as 
conveyors of nutrients, and serve as targets for drugs, pathological factors and 
environmental xenobiotics [88]. Severe Ifosfamide mediated hematotoxicity and bone 
marrow suppression are also reported by many workers [89,90]. Ascorbate (vitamin C) 
is considered to be an important antioxidant in extracellular fluid including blood and 
protects plasma lipids from peroxyl radicals mediated peroxidative damage[91]. 
Ascorbic acid has been reported to cause protective effect against hematological 
toxicity induced by chlorpyrifos[92] and carbamazepine[93] also in rats. The vitamins (C 
and E), supplementation has also been found to be associated with reduced toxic 
effects of ethanol on liver weight and some blood parameters in rabbit[94]. 
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CONCLUSION 
 
 
In conclusion, it may be suggested that combination treatment of Ascorbic 
acid plus Ifosfamide could be very useful in enhancing Ifosfamide mediated 
therapeutic efficacy which involves induction of apoptosis in DL cells with higher 
apoptotic index. Ifosfamide treatment induced hematotoxicity and renal toxicity in the 
host but the treatment with Ascorbic acid plus Ifosfamide showed significant decrease 
in these toxicities indicating a protective effect, thus, indicating differential effects of 
the combined treatment on the cancer cells and other tissues of the host. 
 
 
	
	
	
	
	
	
 
	
	
	
	
	
	
 
CHAPTER – X 
 
 
 
 
 
 
 
Bibliography 
Bibliography	
 
BIBLIOGRAPHY 
1. Cancer Research, UK cancer incidence statistics by age. http://info.cancer 
researchuk.org/cancerstats/incidence/age/,2007. 
2. http://www.who.int/mediacentre/factsheets/fs297/en/,2006. 
3. Kinzler, Kenneth, W., Vogelstein, Bert. Introduction.In, The genetic basis of 
human cancer, 2nd revised ed, McGraw-Hill, Medical Pub. Division, New 
York , 2002, pp.5. 
4. Sasco, AJ., Secretan, MB., Straif, K. Tobacco smoking and cancer: a brief 
review of recent epidemiological evidence.Journal of  Lung cancer.,2004, 45 
(Suppl 2): 3–9.  
5. Biesalski, HK., Bueno de Mesquita, B., Chesson, A. European Consensus 
Statement on Lung Cancer: risk factors and prevention. Lung Cancer Panel. A 
cancer journal for clinicians.,1998, 48 (3): 167–76.  
6. O'Reilly,KM., Mclaughlin, AM., Beckett, WS., Sime, PJ. Asbestos-related 
lung disease. American family physician., 2007,75 (5): 683–8.  
7. English, DR., Armstrong, BK., Kricker, A., Fleming, C. Sunlight and cancer. 
Cancer causes & control.,1997, 8 (3): 271–83.  
8. Pagano, JS., Blaser, M., Buendia, MA. Infectious agents and cancer: criteria 
for a causal relation .Semin Cancer Biol.,2004,14(6):453–71.  
9. Hanahan, D., Weinberg, RA. The hallmarks of cancer. Cell., 2000,100 (1): 
57–70.  
10. Wu, RS., Bonner, WM. Separation of basal histone synthesis from S-phase 
histone synthesis in dividing cells. Cell., 1981, 27 (2 Pt 1): 321–30. 
11. Nelson, DM., Ye, X., Hall, C., Santos, H., Ma, T., Kao, GD., Yen, TJ., Harper, 
JW., Adams, PD. Coupling of DNA synthesis and histone synthesis in S phase 
independent of cyclin/cdk2 activity. Mol. Cell. Biol.,2002, 22 (21): 7459–72. 
12. Cameron, IL., Greulich, RC. Evidence for an essentially constant duration of 
DNA synthesis in renewing epithelia of the adult mouse. J. Cell Biol.,1963, 
18: 31–40. 
13. Rubenstein, Irwin, Susan, M., Wick. Cell. World Book Online Reference 
Center., 2008, 12. 
14. Croce, CM. Oncogenes and cancer. The New England journal of 
medicine.,2008, 358 (5): 502–11. 
Bibliography	
 
15. Knudson, AG. Two genetic hits (more or less) to cancer. Nature reviews 
Cancer.,2001, 1 (2): 157–62. 
16. Danaei, G., Vander Hoorn, S., Lopez, AD., Murray, CJ., Ezzati, M. Causes of 
cancer in the world: comparative risk assessment of nine behavioural and 
environmental risk factors., Lancet,2005, 366 (9499): 1784–93. 
17. Lung Cancer in American Women: Facts, http://www.nationallungcancer 
partnership.org/page.cfm?l=factsWomen. 
18. Buell, P., Dunn ,JE . Cancer mortality among Japanese Issei and Nisei of 
California. Cancer.,1965, 18: 656–64. 
19. Larsson ,SC., Wolk, A. Coffee consumption and risk of liver cancer: a meta-
analysis. Gastroenterology.,2007, 132 (5): 1740–5. 
20. Vogel ,V., Costantino, J., Wickerham ,D., Cronin, W., Cecchini, R., Atkins, J., 
Bevers ,T., Fehrenbacher, L., Pajon ,E., Wade ,J., Robidoux ,A., Margolese, 
R., James ,J., Lippman ,S., Runowicz ,C., Ganz ,P., Reis ,S., Caskill-Stevens 
,W., Ford ,L., Jordan, V., Wolmark ,N. Effects of tamoxifen vs raloxifene on 
the risk of developing invasive breast cancer and other disease outcomes: the 
NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 
.,2006,295 (23): 2727–41. 
21. Thompson,I., Goodman ,P., Tangen ,C., Lucia ,M., Miller, G., Ford ,L., 
Lieber, M., Cespedes, R., Atkins, J., Lippman ,S., Carlin ,S., Ryan ,A., 
Szczepanek, C., Crowley, J., Coltman ,C. The influence of finasteride on the 
development of prostate cancer. N Engl J Med.,2003, 349 (3): 215–24. 
22. Hallak, A., Alon-Baron ,L., Shamir, R., Moshkowitz ,M., Bulvik, B., 
Brazowski, E., Halpern, Z., Arber, N. Rofecoxib reduces polyp recurrence in 
familial polyposis. Dig Dis Sci.,2003, 48 (10): 1998–2002. 
23. Baron ,J., Sandler, R., Bresalier ,R., Quan ,H., Riddell, R., Lanas, A., 
Bolognese, J., Oxenius ,B., Horgan, K., Loftus, S., Morton ,D. A randomized 
trial of rofecoxib for the chemoprevention of colorectal adenomas. 
Gastroenterology.,2006, 131 (6): 1674–82. 
24. Bertagnolli, M., Eagle, C., Zauber, A., Redston, M., Solomon, S., Kim, K., 
Tang, J., Rosenstein, R., Wittes, J., Corle ,D., Hess, T., Woloj ,G., Boisserie 
,F., Anderson ,W., Viner, J., Bagheri ,D., Burn ,J., Chung ,D., Dewar ,T., 
Foley, T., Hoffman, N., Macrae, F., Pruitt, R., Saltzman ,J., Salzberg, B., 
Bibliography	
 
Sylwestrowicz, T., Gordon, G., Hawk, E. Celecoxib for the prevention of 
sporadic colorectal adenomas. N Engl J Med.,2006, 355 (9): 873–84. 
25. Cancer Vaccine Fact Sheet. NCI., 2006. 
26. Liao ,JC., Gregor, P., Wolchok ,JD., Orlandi, F., Craft, D., Leung ,C., 
Houghton, AN., Bergman ,PJ. Vaccination with human tyrosinase DNA 
induces antibody responses in dogs with advanced melanoma. Cancer 
Immun.,2006, 6: 8.  
27. CA Cancer .J Clin., 2009. 
28. Carol,B.,Amy,W.V.Basic principles  of cancer treatments and cancer 
chemotherapy. In pharmacotherapy a pathologic research,3rd ed.elsevier, 
Newyork(Joseph,T; Gary, C.V.; Gary,R.M; Barbara, G.W.; Michael.Eds), 
pp.2403-2411. 
29. Suravi Kalita, Akalesh Kumar Verma, Surya Bali Prasad., Chlorambucil and 
ascorbic acid-mediated anticancer activity and hematological toxicity in 
Dalton's ascites lymphoma-bearing mice., Indian J Exp Biol., 2014 Feb; 
52(2):112-24. 
30. Martha. KR., Gabriel Rosanngkima., Longchar Amenla., Thengton Rongpi., 
Surya B.Prasad., Cisplatin and dietary ascorbic acid mediated changes in the 
mitochondria of dalton’s lymphoma bearing mice. Fundamental and clinical 
Pharmacology, Vol 27, Issue 3, Pages 329-338, June 2013. 
31. Surya Bali Prasad., Gabriel Rosangkima., Bonnie M. Nicol., 
Cyclophosphamide and ascorbic acid-mediated ultrastructural and biochemical 
changes in Dalton's lymphoma cells in vivo Molecular and Cellular 
Pharmacology European Journal of Pharmacology, 645 (2010). 
32. Nicol BM.,Prasad S.B. Sialic acid changes in Dalton's lymphoma-bearing 
mice after cyclophosphamide and cisplatin treatment., Braz J Med Biol 
Res.2002 May; May;35(5): 549-53. 
33. Osama A Badary, Thymoquinone attenuates ifosfamide-induced Fanconi 
syndrome in rats and enhances its antitumor activity in mice, Journal of 
ethnopaharmacology, Nov 1999; Vol 67 (2), 135 - 142 
34. Kristen Borner, Jens Kisro, Svenja K. Bruggemann, Wibke Hagenah, 
STEFAN O.Peters and Thomas Wagner., Metabolism of Ifosfamide to 
Chloroacetaldehyde Contributes to Antitumor Activity In Vivo. Drug 
metabolism and disposition, ASPET Journals (2000). 
Bibliography	
 
35. C Bokemeyer, LM Fels, T Dunn, W Voigt, J Gaedeke, H-J Schmoll, H Stolte 
and H Lentzen., Silibinin protects against cisplatin-induced nephrotoxicity 
without compromising cisplatin or ifosfamide anti-tumour activity., British 
Journal of Cancer (1996) 74, 2036-2041. 
36. Maurie Markman., Thomas Hakes., Bonnie Reichman., John L. Lewis, Jr, 
Stephen Rubin, Walter Jones, Lois Almadrones, Frank Pizzuto, and William 
Hoskins., Ifosfamide and mesna in previously treated advanced epithelial 
ovarian cancer: activity in platinum-resistant disease. Journal of Clinical 
Oncology, Vol 10, No 2 (February), 1992: pp 243-248. 
37. Kuśnierczyk H, Radzikowski C, Paprocka M, et al. Antitumor activity of 
optical isomers of cyclophosphamide, ifosfamide and trofosfamide as 
compared to clinically used racemates., J Immunopharmacol.,  1986; 
8(4):455-80. 
38. W.Brade, S.Seeber, K,Herdrich. The Comparative activity of ifosfamide and 
cyclophosphamide. Cancer Chemotherapy and Pharmacology 1986,volume 
18,issue 2 supplement, pp S1-S9.  
39. Muthu Irulappan Sriram., Selvaraj., Barath Mani Kanth., Kalimuthu., 
Kalishwarala., Sangiliyandi Gurunathan., Antitumor activity of silver 
nanoparticles in Dalton’s lymphoma ascites tumor model. International 
Journal of Nanomedicine, (2010); 5:753-762. 
40. Meghna R Adhvaryu, Narshimha Reddy and Minoo H Parabia, Anti-Tumor 
Activity of Four Ayurvedic Herbs in Dalton Lymphoma Ascites Bearing Mice 
and Their Short-Term In Vitro Cytotoxicity on DLA-Cell-Line.African, J 
Tradit Complement Altern Med. 2008; 5(4): 409–418 , Published online 2008 
Jun 18. 
41. Benjamin RS, Legha SS, Patel SR, Nicaise C. Single-agent ifosfamide studies 
in sarcomas of soft tissue and bone: the M.D. Anderson experience. Cancer 
chemotherapy Pharmacology 1993; 31 Suppl 2:S174-9. 
42. H.Glazman-Kuśnierczyk., Matuszyk J., Radzikowski C., Antitumor Activity 
Evaluation of Bromine-Substituted Analogues of Ifosfamide. 
Immunopharmacology immunotoxicology 1992; 14(4)883-911. 
43. Vanhoefer U., Schleucher N., Klaassen U., Seeber S., Harstrick A. Ifosfamide-
based drug combinations, preclinical evaluation of drug interactions and 
translation into the clinic. Semin oncology, 2000 Feb; 27:8-13 
Bibliography	
 
44. B Samuel Thavamani., Molly Mathew., S.P.Dhanabal. Anticancer activity of 
cissampelos pareira against dalton's lymphoma ascites bearing mice. 
Pharmacognosy Mag., 2014 Jul-Sep; 10(39): 200-206. 
45. Shivakumar.B.S., Ramaiah. M., Hema, M.R.V.P.Vaidya. Evaluation of In-
Vitro Anticancer Activity of Barlaria buxifolia Linn Extracts Against Dalton's 
Lymphoma Ascites Cell line, International Journal of  Medicobiological 
Research.,2012;1(5):297-300. 
46. Purushoth Prabhu, Pannerselvam., Selvakumari.S1., Sivaraman.D. The Invitro 
and Invivo anticancer activity of Ethanolic extract of Canthium Parviflorum 
Lam on DLA and Hela cell lines., International Journal of Drug Development 
& Research., Oct-Dec 2011,Vol.3,Issue 4. 
47. Christian M. Kurbacher., Uwe wagner., Bernd Kolster., Peter E. Andreotti., 
Dieter Krebs., Howard W. Bruckner.,  Ascorbic acid (vitamin C) improves the 
antineoplastic activity of doxorubicin, cisplatin, and paclitaxel in human breast 
carcinoma cells in vitro. Cancer letters, Vol.103, no.2, pp.183-189,1996. 
48. Perrone G, Hideshima T, Ikeda H, Okawa Y, Calabrese E, Gorgun G, Santo L, 
Cirstea D, Raje N, Chauhan D, Baccarani M, Cavo M, Anderson KC. 
Ascorbic acid inhibits antitumor activity of bortezomib in vivo. Leukemia 
2009 Sep; 23(9):1679-86 
49. Yukitoshi Takemuraa, Motohiko satoh., Kiyotoshi satoh., Hironobu Hamada., 
Yoshitaka sekido., Shunichiro Kubota. High dose of ascorbic acid induces cell 
death in mesothelioma cells. Journal of Bbrc.; Apr 2010(2):249-53. 
50. Anirudha giri., Dimos Khynriam., Surya B Prasad. Vitamin C mediated 
protection on cisplatin induced mutagenicity in mice. Mutation research 
fundamendal and Molecular Mechanism of Mutagenesis 12/1998; 139-48. 
51. Steve harakeh., Mona diab-assaf., Jihane c. Khalife., Khalil a. abu-el-ardat., 
Elias baydoun., Aleksandra niedzwiecki., Marwan e. el-sabban., Mathias rath. 
Ascorbic acid induces apoptosis in adult t-cell leukemia. Anticancer research 
27: 289-298 (2007) 
52. Ewan Cameron., Linus Pauling., Brian Leibovitz. Ascorbic Acid and Cancer: 
A Review1. Cancer Research 39, 663-681 , March 1979. Anticancer Research 
29: 2681-2686 (2009) 
53. Aristides polyzos .,Nikolas tsavaris., Helen gogas.,  Antonios., Kostas 
polyzos., Lagadas., Kostas giannakopoulos., Evangelos felekouras., Christos -
Bibliography	
 
tsigris., Theodoros karatzas., Othon papadopoulos., Athanasios giannopoulo. 
Cisplatin–Ifosfamide–Gemcitabine as Salvage Chemotherapy in Ovarian 
Cancer Patients Pretreated with Platinum Compounds and Paclitaxel. 
Anticancer Research 29: 2681-2686 (2009). 
54. Jahnke K, Thiel E, Bechrakis NE, et al. (December 2008). "Ifosfamide or 
trofosfamide in patients with intraocular lymphoma". J. Neurooncol. 93 (2): 
213–7.  
55. Ajithkumar T, Parkinson C, Shamshad F, Murray P (March 2007). 
"Ifosfamide encephalopathy". Clin Oncol (R Coll Radiol) 19 (2): 108–14. 
56. Lami N, Kadota S, Kikuchi T, Momose Y. Chemical and Pharmaceutical 
Bulletin., 1991, 39: 1551-1555.  
57. Aslam M. Asian Medicine and its practice in Britain. In: Evans, W.C. (Ed.), 
Pharmacognosy. Saunders Company Ltd, London. 1996, pp. 499–500.  
58. Chanda, B.K., Sharma A.K., Anand, K.K.J. Ethnopharmacol., 1991, 31: 299-
307. 
59. Rawat A.K.S., Mehrotra S.S., Tripathi C., Shome U. Indian Ethnomedicine., 
1997,56: 61-66. 
60. Adesina S.K. Quarterly J. Crude Drug Research 1979; 17: 84-86. Anonymous. 
The wealth of India Raw Materials CSIRPublication. New Delhi. India. 1988; 
174. 
61. Hiruma I.C.A., Graciosa J.S., Bighetti E.J., Germonsen R.L., Souza B.A.B. J. 
Ethnopharmacol., 2000, 71: 267-74. 
62. Suravi Kalita, Akalesh Kumar Verma, Surya Bali Prasad., Chlorambucil and 
ascorbic acid-mediated anticancer activity and hematological toxicity in 
Dalton's ascites lymphoma-bearing mice., Indian J Exp Biol., 2014 Feb; 
52(2):112-24. 
63. Sathiyanarayanan, L., Shinnathambi, Arulmozi, Chidhambarnathan, N.  Anti 
Carcinogenic activity of Leptadenia  reticulatal against Dalton’s  ascitic 
lymphoma.  Iranian Journal of Pharmacology and Toxicology., 2006, 6: 133-
136. 
Bibliography	
 
64. Jackson, F., Stark, G. Leukemia.  In, clinical pharmacy and therapeutics, 3rd 
Ed, (Roger, W., and Clive, Eds,) Churchill Livingstone Elsevier, New York, 
pp.47-749. 
65. Senthil, K.N., Shrishailappa, B., Santhosh Kumar, H., Ashok, G.  Antitumor 
activity and antioxidant activity of the Methanolic Extract of bark against 
Daltons Lymphoma ascites induced Ascitic and solid tumor in mice.  Indian 
journal of Pharmaceutical sciences., 2007, 3:12-23. 
66. Gupta, M., Mazumder, U.K., Sambath, K.R., SivaKumar, T., Vamsi, M.L.M.  
Antitumor activity and antioxidant status of Caesalpinia bonducella against 
Ehrlich ascites carcinoma in Swiss albino mice.  J Pharmacol Sci., 2004, 
94:177-184. 
67. Spiridon, K.E., Terrestrial Plant-Derived Anticancer Agents and Plants used in 
Anticancer Research.  Crit. Rev. Plant Sci., 2006, 25: 79-113. 
68. Mary, K.T., Kuttan, G.,  Kuttan,  K.  Partial purification of tumor reducing 
principle from Helicanthis elasticus.  Cancer Letter., 1994, 81:53-57. 
69. SanthoshKumar, H., Senthil Kumar, N.,  Reghu, C.H.  Anti tumor activity of 
Methanolic ectract of Hypericum hookerianum on EAC Cell line in Swiss 
albinomice, J.Pharmacological. Sci., 2007, 103:354-359. 
70. Jacqueline, M.H., Darius, J.N., Mathew, J.M., Ronald, D.B.  Blood Lipid 
Profile in Childeren’s with Acute Lymphoblastic Leukemia.  Cancer., 1998, 
83:379-384. 
71. Ronald, A.S.  Disease of White blood cells.  In, Wildman’s Clinical 
Interpretation of Laboratory Tests, 10th Ed, Jaypee Press, New Delhi, 1995, 
pp.164. 
72. Viroj wiwanikit.  High Serum alkaline phosphatase Level in Hospitalized 
Patient.  BMC family practice., 2001, 10:1861,1471-2296. 
73. Amenla, Verma A K & Prasad S B, Dietary ascorbic acidmediated 
augmentation of anti tumor activity and protection against toxicity induced by 
cis-diamminedichloroplatinum-(II) in Dalton’s lymphoma-bearing mice, J 
Cancer Res Updates, 2 (2013) 116. 
Bibliography	
 
74. Nicol B M & Prasad S B, The effects of cyclophosphamide alone and in 
combination with ascorbic acid against murine ascites Dalton’s lymphoma, 
Indian J Pharmacol, 38 (2006) 260. 
75. Martha K R M, Rosangkima G, Longchar A, Rongpi T & Prasad S B, 
Cisplatin- and dietary ascorbic acid-mediated changes in the mitochondria of 
Dalton’s lymphoma-bearing mice, Fundamental Clinical Pharmacol, 27 
(2013) 329. 
76. Sriram M I, Mani Kanth S B, Kalishwaralal K & Gurunathan S, Antitumor 
activity of silver nanoparticles in Dalton’s lymphoma ascites tumor model, Int 
J Nanomed, 5 (2010) 753. 
77. Nicolle A, Proctor S J & Summerfield G P, High dose chlorambucil in the 
treatment of lymphoid malignancies, Leuk Lymph, 45 (2004) 271. 
78. Begleiter, A, Mowat, M, Israels, L G & Johnston, J B, Chlorambucil in 
chronic lymphocytic leukemia—Mechanism of action, Leuk Lymph, 23 (1996) 
187. 
79. Tomenendalova J, Mayer J, Doubek M, Horky D, Rehakova K & Doubek J, 
Chlorambucil and fluderabine as a new pretransplant conditioning for patients 
with chronic lymphocytic leukemia : results of in vivo experiments, 
Veterinarni Medicina, 53(2008)564. 
80. Amrein L, Loignon M, Goulet A C, Dunn M L, Jean-Claude B, Aloyz R & 
Panasci L, Chlorambucil cytotoxicity in malignant B lymphocytes is 
synergistically increased by 2- (morpholin-4-yl)-benzo[h]chomen-4-one 
(NU7026)- mediated inhibition of DNA-double strand break repair via 
inhibition of DNA-dependent protein kinase, J Pharmacology Exp Ther, 
321(3)(2007) 848. 
81. Salem F S, Badr M O T & Neamat-Allah A N F, Biochemical and and 
pathological studies on the effects of levamisole and chlorambucil on Ehrlich 
ascites carcinomabearing mice, Veterinaria Italiana, 47(1)(2011)89. 
82. Park S, Han S, Park C H, Hahm E R, Lee S J, Park H K, Lee S H, Kim W S, 
Jung C W, Park K, , Riordan H D, Kimler B F, Kim K & Lee J H, L-Ascorbic 
acid induces apoptosis in acute myeloid leukemia cells via hydrogen peroxide-
mediated mechanisms, Int J Biochem Cell Biol, 36 (2004) 2180. 
Bibliography	
 
83. Summerfield G P, Taylor P R A, Mounter P J & Proctor S J, High-dose 
chlorambucil for the treatment of chronic lymphocytic leukaemia and low-
grade non-Hodgkin’s lymphoma, Br J Haematol, 116 (2002) 781. 
84. Blumenreich M S, Woodcock T M, Sherrill E J, Richman S P, Gentile P S, 
Epremian B E, Kubota T T & Allegra J C, A phase I trial of chlorambucil 
administered in short pulses in patients with advanced malignancies, Cancer 
Invest, 6 (1988) 371. 
85. Ballinger A, Gastroenterology and anemia, Medicine, 35 (2007) 142. 
86. Tung H T, Cook F W, Wyatt R D & Hamilton P B, The anemia caused by 
aflatoxin, Poult Sci, 54 (1975) 1962. 
87. Durak I, Akyol O, Baseme E, Canbolat O & Kavutcu M, Reduced erythrocyte 
defence mechanisms against free radical toxicity in patients with chronic renal 
failure, Nephron, 66 (1994) 76. 
88. Pickula S, Brandorowicz-Pikula, J, Awasthi, S & Awasthi Y C, ATP-driven 
efflux of glutathione s-conjugates, antitumor drugs and xenobiotics from 
human erythrocytes, Biochem Arch, 12 (1996) 261. 
89. Galton D A G, Wiltshaw E, Szu R L & Dacie J V, The use of chlorambucil 
and steroids in the treatment of chronic lymphocytic leukemia, Br J Haematol, 
7 (1961) 73. 
90. Rudd P, Fries J F & Epstein W V, Irreversible bone marrow failure with 
chlorambucil, J Rheumatol, 2 (1975) 421. 
91. Frei B, England L & Ames B, Ascorbate is an outstanding antioxidant in 
human blood plasma. Proc Natl Acad Sci USA, 86 (1989) 6377. 
92. Ambali S F, Ayo J O, Esievo K A N & Ojo S A, Hemotoxicity induced by 
chronic chlorpyrifos exposure in Wistar rats:mitigating effect of vitamin C, 
Veterinary Med International, 2011(2011)1. doi:10.4061/2011/945439 
93. Thakur S, Eswaran M & Rajalakshmi S G, Amelioration of carbamazepine 
induced oxidative stress and hematotoxicity by vitamin C, Spatula DD, 2012; 
2(3) ( 2012)173. 
94. Shalan M G, Abd Ali W Dh & Shalan A G, The protective efficacy of 
vitamins (C and E), selenium and Silymarin supplements against alcohol 
toxicity. World Rabbit Sci, 15 (2007) 103. 
 
